Cellebrite DI (NASDAQ:CLBT – Get Free Report) announced its earnings results on Thursday. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03), Zacks reports. Cellebrite DI had a negative net margin of 82.28% and a positive return on equity of 122.59%. Cellebrite DI updated its FY 2025 guidance to EPS and its Q1 2025 guidance to EPS.
Cellebrite DI Stock Down 4.9 %
Shares of NASDAQ:CLBT traded down $1.07 during midday trading on Friday, reaching $20.64. The company’s stock had a trading volume of 358,837 shares, compared to its average volume of 1,804,331. The firm has a market cap of $4.25 billion, a price-to-earnings ratio of -13.35, a price-to-earnings-growth ratio of 3.72 and a beta of 1.47. Cellebrite DI has a 1 year low of $9.96 and a 1 year high of $26.30. The business has a 50 day moving average price of $22.57 and a 200 day moving average price of $19.09.
Analyst Ratings Changes
CLBT has been the topic of several analyst reports. Craig Hallum lifted their target price on Cellebrite DI from $23.00 to $24.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Needham & Company LLC reissued a “buy” rating and issued a $28.00 price target on shares of Cellebrite DI in a report on Friday. Finally, JPMorgan Chase & Co. raised their price target on Cellebrite DI from $24.00 to $28.00 and gave the company an “overweight” rating in a report on Tuesday. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Cellebrite DI has an average rating of “Buy” and an average target price of $22.14.
About Cellebrite DI
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Featured Articles
- Five stocks we like better than Cellebrite DI
- Short Selling: How to Short a Stock
- Up 50% in January, Twilio’s Pullback is the Time to Buy
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Watch These 3 Stocks—High Short Interest and Big Upside Potential
- Why Are These Companies Considered Blue Chips?
- Cisco Roars Back: Is the Tech Giant Reborn?
Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.
